ARS Pharmaceuticals Acquires Silverback Therapeutics

Silverback Therapeutics is a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company's lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. It also focuses on developing SBT6290, a product candidate that is in the preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. Silverback Therapeutics was founded in 2016 and is based in Seattle, Washington.